Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Abstract PD13-09: Primary analysis from NEOS trial: A randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received neoadjuvant endocrine therapy (NET) with/without adjuvant chemotherapy (CT)

Hiroji Iwata, Tatsuya Toyama, Naruto Taira, Norikazu Masuda, Yutaka Yamamoto, Tomomi Fujisawa, Shoichiro Ohtani, Masahiro Kashiwaba, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi

Cancer Res (2022) 82 (4_Supplement): PD13-09.

https://doi.org/10.1158/1538-7445.SABCS21-PD13-09

Published: 15 February 2022

View article titled, Abstract PD13-09: Primary analysis from NEOS trial: A randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received neoadjuvant endocrine therapy (NET) with/without adjuvant chemotherapy (CT)

Journal Articles

Abstract P4-07-21: High Tinagl1 expression is a marker of good prognosis in breast cancer

Akiko Kato, Naoto Kondo, Yumi Wanifuchi-Endo, Takashi Fujita, Tomoko Asano, Tomoka Hisada, Yasuaki Uemoto, Mitsuo Terada, Tatsuya Toyama

Cancer Res (2022) 82 (4_Supplement): P4-07-21.

https://doi.org/10.1158/1538-7445.SABCS21-P4-07-21

Published: 15 February 2022

View article titled, Abstract P4-07-21: High <em>Tinagl1</em> expression is a marker of good prognosis in breast cancer

Journal Articles

Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study

Cancer Res (2021) 81 (4_Supplement): PD3-11.

https://doi.org/10.1158/1538-7445.SABCS20-PD3-11

Published: 15 February 2021

View article titled, Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study

Journal Articles

Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)

Cancer Res (2021) 81 (4_Supplement): PD1-09.

https://doi.org/10.1158/1538-7445.SABCS20-PD1-09

Published: 15 February 2021

View article titled, Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)

Journal Articles

Abstract P6-04-11: LLGL2 is involved in resistance to tamoxifen in estrogen receptor-alpha positive breast cancer patients

Tomoka Hisada, Naoto Kondo, Yumi Endo, Tomoko Asano, Yasuaki Uemoto, Sayaka Nishikawa, Yusuke Katagiri, Mitsuo Terada, Akiko Kato, Yu Dong, Hiroyuki Kato, Satoru Takahashi, Tatsuya Toyama

Cancer Res (2020) 80 (4_Supplement): P6-04-11.

https://doi.org/10.1158/1538-7445.SABCS19-P6-04-11

Published: 15 February 2020

View article titled, Abstract P6-04-11: LLGL2 is involved in resistance to tamoxifen in estrogen receptor-alpha positive breast cancer patients

Journal Articles

Abstract P6-07-03: The prognostic impact of HECTD1 E3 ubiquitin ligase expression in breast cancer patients

Yasuaki Uemoto, Naoto Kondo, Yumi Wanifuchi-Endo, Tomoko Asano, Tomoka Hisada, Sayaka Nishikawa, Yusuke Katagiri, Mitsuo Terada, Akiko Kato, Yu Dong, Hiroyuki Kato, Satoru Takahashi, Tatsuya Toyama

Cancer Res (2020) 80 (4_Supplement): P6-07-03.

https://doi.org/10.1158/1538-7445.SABCS19-P6-07-03

Published: 15 February 2020

View article titled, Abstract P6-07-03: The prognostic impact of HECTD1 E3 ubiquitin ligase expression in breast cancer patients

Journal Articles

Abstract OT1-07-06: Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

Cancer Res (2020) 80 (4_Supplement): OT1-07-06.

https://doi.org/10.1158/1538-7445.SABCS19-OT1-07-06

Published: 15 February 2020

View article titled, Abstract OT1-07-06: Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

Journal Articles

Abstract P2-15-01: A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial

Cancer Res (2020) 80 (4_Supplement): P2-15-01.

https://doi.org/10.1158/1538-7445.SABCS19-P2-15-01

Published: 15 February 2020

View article titled, Abstract P2-15-01: A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial

Journal Articles

Abstract P3-14-02: A cohort study to evaluate the efficacy and safety of postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT-cohort study)

Cancer Res (2020) 80 (4_Supplement): P3-14-02.

https://doi.org/10.1158/1538-7445.SABCS19-P3-14-02

Published: 15 February 2020

View article titled, Abstract P3-14-02: A cohort study to evaluate the efficacy and safety of postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT-cohort study)

Journal Articles

Abstract 1112: Forced reduction of DSS1, a member of TREX2 complex, highly sensitizes chemotherapy to breast cancer cells in a BRCA2-independent manner

Kazuhiko Kuwahara, Naomi Gondo, Andri Rezano, Zhenhuan Zhang, Yukari Hato, Kiyotaka Kuzushima, Hiroji Iwata, Tatsuya Toyama, Eisaku Kondo

Cancer Res (2017) 77 (13_Supplement): 1112.

https://doi.org/10.1158/1538-7445.AM2017-1112

Published: 01 July 2017

View article titled, Abstract 1112: Forced reduction of DSS1, a member of TREX2 complex, highly sensitizes chemotherapy to breast cancer cells in a BRCA2-independent manner

Journal Articles

Abstract P5-05-02: Prognostic impact of single-nucleotide polymorphisms (SNPs) in or near the ZNF423 and CTSO genes in estrogen receptor (ER)-positive breast cancer patients receiving adjuvant endocrine therapy

Yukari Hato, Yumi Endo, Nobuyasu Yoshimoto, Tomoko Asano, Mina Yamaguchi, Satoru Takahashi, Tatsuya Toyama

Cancer Res (2015) 75 (9_Supplement): P5-05-02.

https://doi.org/10.1158/1538-7445.SABCS14-P5-05-02

Published: 01 May 2015

View article titled, Abstract P5-05-02: Prognostic impact of single-nucleotide polymorphisms (SNPs) in or near the ZNF423 and CTSO genes in estrogen receptor (ER)-positive breast cancer patients receiving adjuvant endocrine therapy

Journal Articles

Abstract P4-11-22: High expression of LMTK3 is an independent factor indicating a poor prognosis in Japanese estrogen receptor α-positive breast cancer patients

Tatsuya Toyama, Tomoko Asano, Shinya Sato, Nobuyasu Yoshimoto, Yumi Endo, Yukari Hato, Dong Yu, Satoru Takahashi, Yoshitaka Fujii

Cancer Res (2015) 75 (9_Supplement): P4-11-22.

https://doi.org/10.1158/1538-7445.SABCS14-P4-11-22

Published: 01 May 2015

View article titled, Abstract P4-11-22: High expression of LMTK3 is an independent factor indicating a poor prognosis in Japanese estrogen receptor α-positive breast cancer patients

Journal Articles

Abstract P4-07-04: Immunohistochemical determination of arylamine N-acetyltransferase 1 (NAT1) as the target of miR-1290 and prognostic biomarker of breast cancer

Yumi Endo, Hiroko Yamashita, Satoru Takahashi, Shinya Sato, Nobuyasu Yoshimoto, Tomoko Asano, Yukari Hato, Mina Yamaguchi, Yu Dong, Tatsuya Toyama

Cancer Res (2015) 75 (9_Supplement): P4-07-04.

https://doi.org/10.1158/1538-7445.SABCS14-P4-07-04

Published: 01 May 2015

View article titled, Abstract P4-07-04: Immunohistochemical determination of <em>arylamine N-acetyltransferase 1 (NAT1)</em> as the target of miR-1290 and prognostic biomarker of breast cancer

Journal Articles

Abstract P1-14-01: First report of clinicopathological analysis in neoadjuvant treatment phase in NEOS: A randomized study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole

Takehiko Sakai, Hiroji Iwata, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Shoichiro Ohtani, Masahiro Kashiwaba, Naruto Taira, Tatsuya Toyama, Yutaka Yamamoto, Tomomi Fujisawa, Norikazu Masuda, Takuhiro Yamaguchi, Hirofumi Mukai, Yasuo Ohashi

Cancer Res (2015) 75 (9_Supplement): P1-14-01.

https://doi.org/10.1158/1538-7445.SABCS14-P1-14-01

Published: 01 May 2015

View article titled, Abstract P1-14-01: First report of clinicopathological analysis in neoadjuvant treatment phase in NEOS: A randomized study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole

Journal Articles

Abstract LB-256: Estrogen and its receptors alpha and beta in different stages of breast carcinogenesis.

Bo Huang, Yoko Omoto, Hirotaka Iwase, Hiroko Yamashita, Tatsuya Toyama, Margaret Warner, Jan-Åke Gustafsson

Cancer Res (2013) 73 (8_Supplement): LB-256.

https://doi.org/10.1158/1538-7445.AM2013-LB-256

Published: 15 April 2013

View article titled, Abstract LB-256: Estrogen and its receptors alpha and beta in different stages of breast carcinogenesis.

Journal Articles

miR-206 Expression Is Down-regulated in Estrogen Receptor α–Positive Human Breast Cancer

Naoto Kondo, Tatsuya Toyama, Hiroshi Sugiura, Yoshitaka Fujii, Hiroko Yamashita

Cancer Res (2008) 68 (13): 5004–5008.

https://doi.org/10.1158/0008-5472.CAN-08-0180

Published: 01 July 2008

View article titled, miR-206 Expression Is Down-regulated in Estrogen Receptor α–Positive Human Breast Cancer

Journal Articles

Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer

Hiroko Yamashita, Tatsuya Toyama, Maho Hamaguchi, Shunzo Kobayashi, Yoshitaka Fujii

Cancer Res (2006) 66 (8_Supplement): 100.

Published: 15 April 2006

View article titled, Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer

Journal Articles

ING1 Isoforms Differentially Affect Apoptosis in a Cell Age-dependent Manner

Diego Vieyra, Tatsuya Toyama, Yasuo Hara, Donna Boland, Randal Johnston, Karl Riabowol

Cancer Res (2002) 62 (15): 4445–4452.

Published: 01 August 2002

View article titled, ING1 Isoforms Differentially Affect Apoptosis in a Cell Age-dependent Manner

NARROW

Abstract PD13-09: Primary analysis from NEOS trial: A randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received neoadjuvant endocrine therapy (NET) with/without adjuvant chemotherapy (CT)

Abstract P4-07-21: High Tinagl1 expression is a marker of good prognosis in breast cancer

Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study

Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)

Abstract P6-04-11: LLGL2 is involved in resistance to tamoxifen in estrogen receptor-alpha positive breast cancer patients

Abstract P6-07-03: The prognostic impact of HECTD1 E3 ubiquitin ligase expression in breast cancer patients

Abstract OT1-07-06: Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

Abstract P2-15-01: A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial

Abstract P3-14-02: A cohort study to evaluate the efficacy and safety of postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT-cohort study)

Abstract 1112: Forced reduction of DSS1, a member of TREX2 complex, highly sensitizes chemotherapy to breast cancer cells in a BRCA2-independent manner

Abstract P5-05-02: Prognostic impact of single-nucleotide polymorphisms (SNPs) in or near the ZNF423 and CTSO genes in estrogen receptor (ER)-positive breast cancer patients receiving adjuvant endocrine therapy

Abstract P4-11-22: High expression of LMTK3 is an independent factor indicating a poor prognosis in Japanese estrogen receptor α-positive breast cancer patients

Abstract P4-07-04: Immunohistochemical determination of arylamine N-acetyltransferase 1 (NAT1) as the target of miR-1290 and prognostic biomarker of breast cancer

Abstract P1-14-01: First report of clinicopathological analysis in neoadjuvant treatment phase in NEOS: A randomized study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole

Abstract LB-256: Estrogen and its receptors alpha and beta in different stages of breast carcinogenesis.

miR-206 Expression Is Down-regulated in Estrogen Receptor α–Positive Human Breast Cancer

Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer

ING1 Isoforms Differentially Affect Apoptosis in a Cell Age-dependent Manner

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only